

Bicycle

Bicycle Therapeutics to Participate in Upcoming Virtual Investor Conferences

September 3, 2020

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Sep. 3, 2020-- [Bicycle Therapeutics plc](#) (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (*Bicycle*®) technology, today announced that management will participate in the following virtual investor conferences in September:

- Citi 15th Annual BioPharma Virtual Conference on Thursday, September 10, 2020
- Goldman Sachs 10th Annual Biotech Symposium on Friday, September 11, 2020
- H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020; presentation at 1:00 p.m. ET
- Cantor Global Healthcare Conference on Wednesday, September 16, 2020; presentation at 9:20 a.m. ET
- Oppenheimer Fall Healthcare Life Sciences & Medtech Summit on Monday, September 21, 2020; presentation at 10:50 a.m. ET

A live webcast of each presentation will be accessible in the Investors & Media section of Bicycle's website at www.bicycletherapeutics.com. Archived replays of the webcasts will be available for 90 days following the presentation dates.

About Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as *Bicycles*®, for diseases that are underserved by existing therapeutics. *Bicycles* are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making *Bicycles* attractive candidates for drug development. Bicycle's lead product candidate, BT1718, a *Bicycle* Toxin Conjugate (BTC) that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a Company-sponsored Phase I/II study. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200903005103/en/): <https://www.businesswire.com/news/home/20200903005103/en/>

Investor and Media Contact:

Bicycle Therapeutics
Maren Killackey
maren.killackey@bicycletx.com
+1-617-203-8300

Source: Bicycle Therapeutics plc